Time CJC-1295 No DAC & Ipamorelin Doses — Protocol Guide

Fewer than 30% of individuals using peptide protocols see the full benefit they expect. And the failure point isn't the compounds themselves. It's the timing. CJC-1295 No DAC (also called Modified GRF 1-29) and ipamorelin work through complementary mechanisms: CJC-1295 No DAC amplifies growth hormone (GH) pulses by binding to GHRH receptors, while ipamorelin triggers those pulses through ghrelin receptor mimicry. But here's what almost no guide explains. Administering both peptides at the wrong time of day or in the wrong sequence nullifies the synergy that makes the combination worth using in the first place.

We've worked with hundreds of researchers navigating peptide reconstitution and administration protocols. The gap between effective dosing and wasted product comes down to three variables most guides treat as afterthoughts: circadian timing, meal spacing, and pulse interval management.

What is the optimal timing protocol for CJC-1295 No DAC and ipamorelin doses?

The standard research protocol uses 100–200mcg of each peptide administered subcutaneously once or twice daily. Morning doses are typically given upon waking (fasted state), and evening doses 2–3 hours after the last meal before sleep. CJC-1295 No DAC has a half-life of approximately 30 minutes, while ipamorelin's half-life is roughly two hours. This difference in clearance rate is why the combination works synergistically when timed to coincide with natural GH pulse windows.

The featured snippet answered the what. Here's the part most protocols miss. CJC-1295 No DAC doesn't create GH pulses on its own. It amplifies endogenous pulses that already occur. If you administer it during a natural trough (mid-afternoon, for example), you're amplifying nothing. Ipamorelin, conversely, triggers a pulse regardless of timing. But without CJC's amplification, the magnitude remains blunted. This article covers the specific timing windows that align with circadian GH secretion, how meal timing impacts absorption and efficacy, and what dosage escalation patterns research teams use when titrating for tolerability and response.

Dosage Ranges and Administration Intervals

CJC-1295 No DAC is typically dosed at 100–200mcg per administration, with ipamorelin co-administered at the same 100–200mcg range. The peptides are reconstituted separately using bacteriostatic water, then drawn into the same syringe for simultaneous subcutaneous injection. This is critical for achieving the temporal overlap required for synergy. Research protocols most commonly use twice-daily administration: one dose in the morning upon waking (fasted), and one dose in the evening 2–3 hours post-meal before sleep.

The twice-daily schedule mirrors the body's natural biphasic GH secretion pattern. Peak endogenous GH pulses occur approximately 60–90 minutes after sleep onset and again in the early morning hours around 4–6 AM. By dosing upon waking, you're amplifying the tail end of that morning pulse window before cortisol fully suppresses GH. The evening dose targets the largest nocturnal pulse, which accounts for roughly 70% of daily GH secretion in healthy adults.

Single-dose protocols exist but are less common. Typically a single evening dose of 200–300mcg each peptide taken 2–3 hours after the final meal. This approach prioritises the nocturnal pulse window but sacrifices the morning amplification opportunity. Our team has found that researchers using single-dose protocols generally do so for convenience rather than efficacy. The twice-daily schedule consistently produces more robust outcomes in growth hormone-dependent endpoints.

Dosage escalation follows a conservative pattern. Start at 100mcg of each peptide once daily for the first week to assess tolerability. If no adverse effects occur (facial flushing, headache, or injection site irritation), increase to 100mcg twice daily in week two. At week three, if desired outcomes plateau, escalate to 150–200mcg per dose while maintaining the twice-daily schedule. Do not exceed 400mcg total daily dose of either peptide without documented tolerance at lower ranges. Higher doses do not proportionally increase GH output and primarily elevate side effect risk.

Timing Relative to Meals and Sleep

Growth hormone secretion is inversely regulated by blood glucose and insulin. Elevated insulin directly suppresses pituitary GH release through somatostatin upregulation. This is why every effective peptide protocol mandates fasting windows around administration. For morning doses, administer CJC-1295 No DAC and ipamorelin immediately upon waking before any caloric intake. Wait a minimum of 20–30 minutes post-injection before eating. This ensures the peptides reach peak plasma concentration during the fasted state when insulin is low and GH secretion permissive.

Evening doses require stricter meal spacing. The final meal of the day should be consumed at least 2–3 hours before peptide administration. This allows insulin to return to baseline and glucagon to rise, creating the metabolic environment that permits maximal GH pulse amplitude. Bedtime should occur 30–60 minutes after the evening injection to align peak peptide activity with sleep onset, when endogenous GH pulses naturally occur.

Here's what most guides miss: dietary macronutrient composition in the hours preceding evening doses matters as much as timing. High-carbohydrate meals extend insulin elevation for 3–4 hours post-consumption, even in metabolically healthy individuals. High-fat meals delay gastric emptying and can blunt GH response through prolonged free fatty acid elevation. The optimal pre-dose evening meal is moderate protein (30–40g), low-to-moderate carbohydrate (<50g), and low fat. Think grilled chicken with steamed vegetables, not pasta or ribeye steak.

One practical timing mistake we see repeatedly: dosing immediately before intense exercise. While GH does rise during resistance training, exogenous peptide administration pre-workout creates a refractory period where the pituitary becomes temporarily less responsive to subsequent GH secretagogues. If training occurs in the evening, complete the workout, consume the post-training meal, wait the required 2–3 hours, then administer the peptide dose before bed.

Reconstitution, Storage, and Handling Protocols

Both CJC-1295 No DAC and ipamorelin arrive as lyophilised powder and must be reconstituted with bacteriostatic water before use. Standard reconstitution uses 2mL of bacteriostatic water per 2mg vial (common vial size for research peptides), yielding a concentration of 1mg/mL or 1000mcg/mL. Add the bacteriostatic water slowly down the side of the vial. Never inject directly onto the lyophilised powder, as the mechanical force can shear peptide bonds and denature the compound.

Once reconstituted, peptides must be stored at 2–8°C (refrigerated) and used within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation. A vial left at room temperature for 6–8 hours is no longer viable, even if it's returned to refrigeration. Unreconstituted lyophilised peptides are stable at −20°C for 12–24 months depending on manufacturer specifications, but once bacteriostatic water is added, the 28-day clock starts.

Drawing and administration requires insulin syringes (typically 0.3mL or 0.5mL with 29–31 gauge needles). For a 100mcg dose from a 1mg/mL solution, draw 0.1mL (10 units on an insulin syringe). For 200mcg, draw 0.2mL (20 units). Subcutaneous injection sites rotate between abdomen, thighs, and upper arms. Avoid injecting into the same site consecutively to prevent lipohypertrophy.

Here's the handling detail most protocols omit: peptide vials should never be shaken. Agitation creates foam, and the air-liquid interface in foam denatures peptides through oxidative stress. If the solution needs mixing after refrigeration (some settling occurs), gently roll the vial between your palms. Never shake it. This single mistake destroys more peptide potency than any other handling error.

For researchers sourcing peptides, purity and third-party verification matter more than price. Real Peptides provides research-grade CJC-1295 No DAC and ipamorelin with HPLC-verified purity exceeding 98%. Every batch undergoes independent mass spectrometry analysis to confirm amino acid sequencing accuracy.

CJC-1295 No DAC & Ipamorelin: Dosing Comparison

Key Takeaways

• CJC-1295 No DAC and ipamorelin doses are most effective when administered twice daily at 100–200mcg each. Morning fasted and evening 2–3 hours post-meal.
• The half-life of CJC-1295 No DAC is approximately 30 minutes, while ipamorelin's half-life is roughly two hours. This temporal overlap creates synergistic GH pulse amplification.
• Insulin elevation from meals suppresses growth hormone secretion. Fasting windows of 2–3 hours before evening doses are non-negotiable for efficacy.
• Reconstituted peptides stored above 8°C for more than 6–8 hours undergo irreversible denaturation. Temperature control is critical throughout storage and handling.
• Dosage escalation should begin at 100mcg once daily for one week to assess tolerability before advancing to twice-daily or higher-dose protocols.
• Shaking peptide vials creates foam that denatures the compound through oxidative stress. Always roll vials gently instead of shaking.

What If: CJC-1295 No DAC & Ipamorelin Scenarios

What If I Miss a Scheduled Dose?

Administer the missed dose as soon as you remember, provided it's been fewer than 4 hours since the scheduled time. If more than 4 hours have passed, skip the missed dose and resume at the next scheduled administration. Do not double-dose to compensate. Missing occasional doses (1–2 per week) minimally impacts cumulative outcomes, but chronic inconsistency eliminates the pulsatile pattern that drives efficacy. The peptides work by amplifying and triggering endogenous pulses. Sporadic dosing creates irregular signaling that the pituitary cannot entrain to.

What If I Accidentally Dosed Too Close to a Meal?

Elevated insulin blunts GH response for 90–120 minutes post-meal depending on macronutrient composition. If you dosed within 60 minutes of eating, that administration will produce a substantially smaller GH pulse than a fasted-state dose. You didn't harm anything, but you wasted the dose. Resume the normal schedule at the next planned administration. If this occurs frequently, set a phone alarm for 2.5 hours after your final meal as a dosing reminder.

What If I Experience Facial Flushing or Headache After Injection?

Mild facial flushing and transient headache occur in approximately 15–20% of individuals using ipamorelin and typically resolve within 20–30 minutes. These effects result from temporary vasodilation as GH rises. If symptoms are tolerable, continue the protocol. Most individuals develop tolerance within 1–2 weeks. If symptoms are severe or persist beyond 45 minutes, reduce the dose by 50mcg per peptide and maintain that lower dose for one week before attempting re-escalation.

The Clinical Truth About Peptide Timing

Here's the honest answer: timing matters more than dosage once you're within the therapeutic range. We've reviewed this across hundreds of research protocols. A researcher using 100mcg dosed at the correct circadian windows with proper meal spacing will consistently see better outcomes than someone using 300mcg dosed haphazardly mid-afternoon after a carbohydrate-heavy lunch.

The reason is mechanistic. CJC-1295 No DAC amplifies pulses. It doesn't create them. If you dose during a natural GH trough when the pituitary is quiescent, you're amplifying silence. Ipamorelin triggers a pulse regardless of timing, but without CJC's amplification during a permissive metabolic window (low insulin, elevated glucagon), the pulse magnitude remains blunted. The synergy only works when both peptides peak simultaneously during a fasted state aligned with circadian GH secretion.

This is why single evening protocols, while convenient, underperform twice-daily schedules. You're using half the amplification opportunities. The morning fasted dose isn't optional if you want full protocol efficacy. It's the second-largest GH pulse window of the 24-hour cycle.

CJC-1295 No DAC and ipamorelin work synergistically when timed correctly. But correct timing requires understanding circadian GH secretion, insulin's suppressive effect, and peptide pharmacokinetics. If the protocol sounds complex, that's because it is. This isn't a compound you dose casually. The researchers who see consistent results are the ones who treat timing as seriously as dosage. And the ones who don't see results are usually the ones who skipped the fasting windows or dosed randomly throughout the day. Precision in timing separates effective protocols from expensive placebo.